|
1
|
Cui X, Li Z, Gao J, Gao PJ, Ni YB and Zhu
JY: Elevated CXCL1 increases hepatocellular carcinoma
aggressiveness and is inhibited by miRNA-200a. Oncotarget.
7:65052–65066. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li
G, Xie J and Chen P: A novel miR-219-SMC4-JAK2/Stat3 regulatory
pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res.
33:552014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li J, Qiu X, Guo W, Yan B and Zhang S:
Prospective analysis of tiopronin in prevention of sorafenib and
antiviral therapy inducing liver toxicity in advanced hepatitis B
virus-related hepatocellular carcinoma. Med Oncol. 32:2382015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen J, Rajasekaran M, Xia H, Zhang X,
Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL,
et al: The microtubule-associated protein PRC1 promotes early
recurrence of hepatocellular carcinoma in association with the
Wnt/β-catenin signalling pathway. Gut. 65:1522–1534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shirvani-Dastgerdi E, Schwartz RE and
Ploss A: Hepatocarcinogenesis associated with hepatitis B, delta
and C viruses. Curr Opin Virol. 20:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsai CL, Hsu FM and Cheng JC: How to
improve therapeutic ratio in radiotherapy of HCC. Liver Cancer.
5:210–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trojan J, Zangos S and Schnitzbauer AA:
Diagnostics and treatment of hepatocellular carcinoma in 2016:
Standards and developments. Visc Med. 32:116–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerjee R, Russo N, Liu M, Basrur V,
Bellile E, Palanisamy N, Scanlon CS, Van Tubergen E, Inglehart RC,
Metwally T, et al: TRIP13 promotes error-prone nonhomologous end
joining and induces chemoresistance in head and neck cancer. Nat
Commun. 5:45272014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye Q, Rosenberg SC, Moeller A, Speir JA,
Su TY and Corbett KD: TRIP13 is a protein-remodeling AAA+ ATPase
that catalyzes MAD2 conformation switching. Elife. 4:42015.
View Article : Google Scholar
|
|
10
|
Ma HT and Poon RYC: TRIP13 regulates both
the activation and inactivation of the spindle-assembly checkpoint.
Cell Reports. 14:1086–1099. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tipton AR, Wang K, Oladimeji P, Sufi S, Gu
Z and Liu ST: Identification of novel mitosis regulators through
data mining with human centromere/kinetochore proteins as group
queries. BMC Cell Biol. 13:152012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tao Y, Yang G, Yang H, Song D, Hu L, Xie
B, Wang H, Gao L, Gao M, Xu H, et al: TRIP13 impairs mitotic
checkpoint surveillance and is associated with poor prognosis in
multiple myeloma. Oncotarget. 8:26718–26731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang K, Sturt-Gillespie B, Hittle JC,
Macdonald D, Chan GK, Yen TJ and Liu ST: Thyroid hormone receptor
interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic
checkpoint-silencing protein. J Biol Chem. 289:23928–23937. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson CR, Hwang T, Chen PH and Bhalla N:
TRIP13PCH-2 promotes Mad2 localization to unattached
kinetochores in the spindle checkpoint response. J Cell Biol.
211:503–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van Kester MS, Borg MK, Zoutman WH,
Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R,
Willemze R and Tensen CP: A meta-analysis of gene expression data
identifies a molecular signature characteristic for tumor-stage
mycosis fungoides. J Invest Dermatol. 132:2050–2059. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou K, Zhang W, Zhang Q, Gui R, Zhao H,
Chai X, Li Y, Wei X and Song Y: Loss of thyroid hormone receptor
interactor 13 inhibits cell proliferation and survival in human
chronic lymphocytic leukemia. Oncotarget. 8:25469–25481.
2017.PubMed/NCBI
|
|
18
|
Kurita K, Maeda M, Mansour MA, Kokuryo T,
Uehara K, Yokoyama Y, Nagino M, Hamaguchi M and Senga T: TRIP13 is
expressed in colorectal cancer and promotes cancer cell invasion.
Oncol Lett. 12:5240–5246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miniowitz-Shemtov S, Eytan E, Kaisari S,
Sitry-Shevah D and Hershko A: Mode of interaction of TRIP13
AAA-ATPase with the Mad2-binding protein p31comet and with mitotic
checkpoint complexes. Proc Natl Acad Sci USA. 112:11536–11540.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reid DA and Rothenberg E: Repair of
chromosomal breaks by NHEJ. Oncotarget. 6:15730–15731. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hentges P, Waller H, Reis CC, Ferreira MG
and Doherty AJ: Cdk1 restrains NHEJ through phosphorylation of
XRCC4-like factor Xlf1. Cell Reports. 9:2011–2017. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang LY, Chen LS, Sun R, Ji SJ, Ding YY,
Wu J and Tian Y: Effects of expression level of DNA repair-related
genes involved in the NHEJ pathway on radiation-induced cognitive
impairment. J Radiat Res. 54:235–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartlett EJ, Brissett NC, Plocinski P,
Carlberg T and Doherty AJ: Molecular basis for DNA strand
displacement by NHEJ repair polymerases. Nucleic Acids Res.
44:2173–2186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Newman EA, Lu F, Bashllari D, Wang L,
Opipari AW and Castle VP: Alternative NHEJ pathway components are
therapeutic targets in high-risk neuroblastoma. Mol Cancer Res.
13:470–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pascale RM, Joseph C, Latte G, Evert M,
Feo F and Calvisi DF: DNA-PKcs: A promising therapeutic target in
human hepatocellular carcinoma? DNA Repair. 47:12–20. 2016.
View Article : Google Scholar : PubMed/NCBI
|
